Aspen buys rights to market thrombolytic drugs in China
Aspen Pharmacare has added China to the countries where it owns the rights to two thrombolytic medications. It has also cancelled a sub-Saharan Africa collaboration agreement with the UK group GlaxoSmithKline. The deal, first announced on September 12, appears to be an exchange valued at £45m. This was the option amount agreed to include China when Aspen acquired the rights to Fraxiparine and Arixtr in most countries in 2014. GlaxoSmithKline, in turn, has paid Aspen £45m to cancel its sub-Saharan Africa collaboration agreement with subsidiary Pharmacare. Aspen said on Tuesday it "is pleased to announce that these transactions completed on December 31". In the September statement, Aspen said the sub-Saharan Africa collaboration generated about R2.1bn in revenue during its 2015 financial year. Ending the collaboration "would enable GlaxoSmithKline to focus on its recently communicated strategic initiatives in Africa". "Aspen is retaining its existing African operations in Kenya, Tanza...
Would you like to comment on this article?
Sign up (it's quick and free) or sign in now.
Please read our Comment Policy before commenting.
Subscribe now to unlock this article.
Support BusinessLIVE’s award-winning journalism for R129 per month (digital access only).
There’s never been a more important time to support independent journalism in SA. Our subscription packages now offer an ad-free experience for readers.
Cancel anytime.
Questions? Email helpdesk@businesslive.co.za or call 0860 52 52 00. Got a subscription voucher? Redeem it now.